Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Fertility and Sterility|September 11, 2024
Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related painFelipe Arbelaez, Hee-Koung Joeng, Azher Hussain, et al.
Pharmacology Research & Perspectives|February 2, 2022
Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humansJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
Clinical Pharmacology in Drug Development|November 25, 2021
Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate PitavastatinJacqueline B McCrea, Azher Hussain, Bennett Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2024
Oncology Combination Drug Development Strategies for Project OptimusTimothy A Yap, Julie Bullock, Susan Chong, et al.
Clinical Pharmacology in Drug Development|June 19, 2021
Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
Bioanalysis|July 11, 2020
Clinical application of volumetric absorptive microsampling to the gefapixant development programBrad Roadcap, Azher Hussain, Dan Dreyer, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2023
Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixantAkshita Chawla, Anna Largajolli, Azher Hussain, et al.
British Journal of Clinical Pharmacology|June 22, 2018
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasisSauzanne Khalilieh, Azher Hussain, Diana Montgomery, et al.
Journal of Clinical Pharmacology|April 23, 2024
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy AdultsJesse C Nussbaum, Azher Hussain, Peter Butera, et al.
ERJ Open Research|December 2, 2020
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic coughDavid R Muccino, Alyn H Morice, Surinder S Birring, et al.
Pageof 3